Press Releases

2019.02.22 Corporate PDF (89KB)
Daiichi Sankyo Announces Organizational Restructuring Effective April 1, 2019 in Japan
2019.02.22 Corporate PDF (121KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2019.02.06 R&D PDF (88KB)
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
2019.01.31 Corporate PDF (143KB)
Daiichi Sankyo Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant and Company Split (Simple Absorption-type Company Split)
2019.01.15 R&D PDF (271KB)
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
2019.01.10 R&D PDF (178KB)
Daiichi Sankyo, Mitsubishi UFJ Capital and Tokyo Institute of Technology Announce Open Innovation Research on iPS Cell-derived Insulin Producing Cells in Japan
2019.01.08 Products PDF (111KB)
Daiichi Sankyo Announces Marketing Approval in Japan of “Tarlige? Tablets” for Pain Treatment
2019.01.08 Products PDF (91KB)
Daiichi Sankyo Announces Approval of MINNEBRO(TM) Tablets for the Treatment of Hypertension in Japan
2019.01.08 Products PDF (175KB)
Pediatric Dosage and Administration Approved for Anti-epileptic Drug VIMPAT? Tablets 50 mg and 100 mg
2019.01.07 Corporate PDF (74KB)
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.

credit free sitemap sbobet168 online slots 1xbet live Freeonline m88 bet link vo m88 W88slots